B2 Prognostic Score: External Validation of a Clinical Decision-making Tool for Metastatic Breast Cancer
The B2 Prognostic Score (B2PS) is a clinical decision-making tool in metastatic breast cancer (MBC) that provides risk classification based on routine parameters. This study validates the B2PS in an independent series of MBC for the whole study group and for each intrinsic subtype. We analyzed 641 m...
Saved in:
| Published in: | Clinical breast cancer Vol. 19; no. 5; pp. 333 - 339 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Elsevier Inc
01-10-2019
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The B2 Prognostic Score (B2PS) is a clinical decision-making tool in metastatic breast cancer (MBC) that provides risk classification based on routine parameters. This study validates the B2PS in an independent series of MBC for the whole study group and for each intrinsic subtype.
We analyzed 641 metastasized patients, treated in 17 German certified breast cancer centers between 2001 and 2009. They were classified into low, intermediate, and high-risk groups according to B2PS. Overall survival (OS) curves for the various B2PS groups were compared with Kaplan-Meier method.
According to the B2PS formula, 42.3% of patients were classified as low risk, 25.4% as intermediate risk and 32.3% as high risk. Intermediate- and high-risk patients had a statistically significant decreased OS compared with B2PS low-risk patients: (intermediate-risk: hazard ratio, 1.36; 95% confidence interval, 1.04-1.77; P = .023; high-risk: hazard ratio, 2.62; 95% confidence interval, 2.06-3.32; P < .001). The 5-year survival rates of low-, intermediate-, and high-risk patients were 41.3%, 26.9%, and 10.2%, respectively. The distribution of B2PS risk groups varied significantly within the intrinsic subtypes. For each intrinsic subtype, B2PS gives an additional risk classification.
This study demonstrates the reproducibility of the B2PS based on routinely assessable parameters and confirms its prognostic value in an independent entire cohort of MBC as well as in the separate intrinsic subtypes. It therefore can help in counseling and individualizing the therapeutic regimens of those patients.
The B2 Prognostic Score (B2PS) is a decision-making tool in metastatic breast cancer. A total of 641 patients treated between 2001 and 2009 were classified into risk groups based on the B2PS, and survival parameters were compared. Intermediate- and high-risk groups showed decreased survival, and the distribution of risk groups varied within the intrinsic subtypes. The B2PS helps in counseling patients with metastatic breast cancer. |
|---|---|
| AbstractList | BACKGROUNDThe B2 Prognostic Score (B2PS) is a clinical decision-making tool in metastatic breast cancer (MBC) that provides risk classification based on routine parameters. This study validates the B2PS in an independent series of MBC for the whole study group and for each intrinsic subtype. PATIENTS AND METHODSWe analyzed 641 metastasized patients, treated in 17 German certified breast cancer centers between 2001 and 2009. They were classified into low, intermediate, and high-risk groups according to B2PS. Overall survival (OS) curves for the various B2PS groups were compared with Kaplan-Meier method. RESULTSAccording to the B2PS formula, 42.3% of patients were classified as low risk, 25.4% as intermediate risk and 32.3% as high risk. Intermediate- and high-risk patients had a statistically significant decreased OS compared with B2PS low-risk patients: (intermediate-risk: hazard ratio, 1.36; 95% confidence interval, 1.04-1.77; P = .023; high-risk: hazard ratio, 2.62; 95% confidence interval, 2.06-3.32; P < .001). The 5-year survival rates of low-, intermediate-, and high-risk patients were 41.3%, 26.9%, and 10.2%, respectively. The distribution of B2PS risk groups varied significantly within the intrinsic subtypes. For each intrinsic subtype, B2PS gives an additional risk classification. CONCLUSIONSThis study demonstrates the reproducibility of the B2PS based on routinely assessable parameters and confirms its prognostic value in an independent entire cohort of MBC as well as in the separate intrinsic subtypes. It therefore can help in counseling and individualizing the therapeutic regimens of those patients. The B2 Prognostic Score (B2PS) is a clinical decision-making tool in metastatic breast cancer (MBC) that provides risk classification based on routine parameters. This study validates the B2PS in an independent series of MBC for the whole study group and for each intrinsic subtype. We analyzed 641 metastasized patients, treated in 17 German certified breast cancer centers between 2001 and 2009. They were classified into low, intermediate, and high-risk groups according to B2PS. Overall survival (OS) curves for the various B2PS groups were compared with Kaplan-Meier method. According to the B2PS formula, 42.3% of patients were classified as low risk, 25.4% as intermediate risk and 32.3% as high risk. Intermediate- and high-risk patients had a statistically significant decreased OS compared with B2PS low-risk patients: (intermediate-risk: hazard ratio, 1.36; 95% confidence interval, 1.04-1.77; P = .023; high-risk: hazard ratio, 2.62; 95% confidence interval, 2.06-3.32; P < .001). The 5-year survival rates of low-, intermediate-, and high-risk patients were 41.3%, 26.9%, and 10.2%, respectively. The distribution of B2PS risk groups varied significantly within the intrinsic subtypes. For each intrinsic subtype, B2PS gives an additional risk classification. This study demonstrates the reproducibility of the B2PS based on routinely assessable parameters and confirms its prognostic value in an independent entire cohort of MBC as well as in the separate intrinsic subtypes. It therefore can help in counseling and individualizing the therapeutic regimens of those patients. The B2 Prognostic Score (B2PS) is a decision-making tool in metastatic breast cancer. A total of 641 patients treated between 2001 and 2009 were classified into risk groups based on the B2PS, and survival parameters were compared. Intermediate- and high-risk groups showed decreased survival, and the distribution of risk groups varied within the intrinsic subtypes. The B2PS helps in counseling patients with metastatic breast cancer. |
| Author | Leinert, Elena Bartmann, Catharina Stueber, Tanja Nadine Diessner, Joachim Woeckel, Achim Wischnewsky, Manfred Stein, Roland Gregor |
| Author_xml | – sequence: 1 givenname: Tanja Nadine surname: Stueber fullname: Stueber, Tanja Nadine email: Stueber_T@ukw.de organization: Department for Obstetrics and Gynecology, University of Würzburg Medical School, Würzburg, Germany – sequence: 2 givenname: Manfred surname: Wischnewsky fullname: Wischnewsky, Manfred organization: Department of Mathematics and Computer Science, University of Bremen, Bremen, Germany – sequence: 3 givenname: Elena surname: Leinert fullname: Leinert, Elena organization: Department for Obstetrics and Gynecology, University of Ulm Medical School, Ulm, Germany – sequence: 4 givenname: Joachim surname: Diessner fullname: Diessner, Joachim organization: Department for Obstetrics and Gynecology, University of Würzburg Medical School, Würzburg, Germany – sequence: 5 givenname: Catharina surname: Bartmann fullname: Bartmann, Catharina organization: Department for Obstetrics and Gynecology, University of Würzburg Medical School, Würzburg, Germany – sequence: 6 givenname: Roland Gregor surname: Stein fullname: Stein, Roland Gregor organization: Department for Obstetrics and Gynecology, University of Würzburg Medical School, Würzburg, Germany – sequence: 7 givenname: Achim surname: Woeckel fullname: Woeckel, Achim organization: Department for Obstetrics and Gynecology, University of Würzburg Medical School, Würzburg, Germany |
| BookMark | eNp9UE1P3DAQtSqQCkv_QE8-cknqj8RJUC-wUKgEAqnbXq3ZyZh6m7XBDoj--3q1PXOaNzPvPem9Y3YQYiDGPktRSyHNl02N0xprJeRQi6YWsv3AjuSg-0oYYw4KbpWpeiWGj-w4540QymgpjtjvC8UfUnwMMc8e-Q-Mic741dtMKcDEf8HkR5h9DDw6Dnw5-eCxPC4JfS7nagt_fHjkqxgn7mLidzRDnmFndpGoQL6EgJRO2KGDKdOn_3PBfn67Wi1vqtv76-_L89sKpRqaSpJpug7lmpRWaxROgxhhQAAHXY_otOudG9YtoSnUdlBa6rGTVBYwndELdrr3fUrx-YXybLc-I00TBIov2SrV6l7rrm8KVe2pmGLOiZx9Sn4L6a-Vwu5qtRu7q9XuarWisaXWIvq6F1EJ8eop2YyeSsLRJ8LZjtG_J_8HyGKDCw |
| Cites_doi | 10.1093/annonc/mdt429 10.1056/NEJMoa1810527 10.1093/annonc/mdt539 10.1007/s10549-009-0687-4 10.1200/JCO.2011.38.8595 10.1007/s10549-013-2743-3 10.1038/bjc.2015.127 10.1200/JCO.2011.37.2482 10.1158/1055-9965.EPI-16-0889 10.1007/s00404-016-4225-4 10.1200/JCO.2018.78.9909 10.1016/j.breast.2018.04.002 10.4143/crt.2017.443 10.1007/s10549-013-2620-0 10.1159/000264617 10.1093/annonc/mdr304 10.1016/S1470-2045(17)30313-3 10.1016/j.breast.2017.10.008 10.1200/JCO.2017.73.7585 10.1016/j.ejca.2011.06.020 10.1093/annonc/mdn424 10.1016/0305-7372(87)90017-X 10.1056/NEJMoa1413513 10.1038/35021093 |
| ContentType | Journal Article |
| Copyright | 2019 Elsevier Inc. |
| Copyright_xml | – notice: 2019 Elsevier Inc. |
| DBID | AAYXX CITATION 7X8 |
| DOI | 10.1016/j.clbc.2019.04.015 |
| DatabaseName | CrossRef MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1938-0666 |
| EndPage | 339 |
| ExternalDocumentID | 10_1016_j_clbc_2019_04_015 S152682091830867X |
| GroupedDBID | --- --K --M .1- .FO .XZ .~1 0R~ 1P~ 1~. 29B 4.4 457 4G. 53G 5GY 6J9 6PF 7-5 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQQT AAQXK AAWTL AAXUO ABBQC ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEGXH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF DU5 EBD EBS EFJIC EFLBG EJD EMB EMOBN F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM LCYCR M41 MET MO0 O-L O9- OAUVE OBH OC~ OHH OO- OVD P-8 P-9 PC. Q38 R2- ROL SDF SEL SES SPCBC SSH SSZ SV3 T5K TEORI UDS Z5R ~G- AAQFI AAXKI AAYXX AFJKZ AKRWK CITATION 7X8 |
| ID | FETCH-LOGICAL-c1294-1e6477c1be232bc0f3a0da9caafa78ccf3f8ff9b5ec6e64592313d71ee64a6763 |
| ISSN | 1526-8209 |
| IngestDate | Fri Oct 25 22:26:06 EDT 2024 Thu Sep 26 19:33:27 EDT 2024 Fri Feb 23 02:30:34 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Metastatic breast cancer Intrinsic subgroups Survival Prognostic score |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c1294-1e6477c1be232bc0f3a0da9caafa78ccf3f8ff9b5ec6e64592313d71ee64a6763 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PQID | 2253833784 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2253833784 crossref_primary_10_1016_j_clbc_2019_04_015 elsevier_sciencedirect_doi_10_1016_j_clbc_2019_04_015 |
| PublicationCentury | 2000 |
| PublicationDate | October 2019 2019-10-00 20191001 |
| PublicationDateYYYYMMDD | 2019-10-01 |
| PublicationDate_xml | – month: 10 year: 2019 text: October 2019 |
| PublicationDecade | 2010 |
| PublicationTitle | Clinical breast cancer |
| PublicationYear | 2019 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Slamon, Nevin, Chia (bib5) 2018; 36 Puente, López-Tarruella, Ruiz (bib22) 2010; 122 Perou, Sørlie, Eisen (bib24) 2000; 406 Swain, Baselga, Kim (bib9) 2015; 372 Xiong, Deng, Huang (bib23) 2018; 50 Lindstrom, Karlsson, Wilking (bib26) 2012; 30 Kreienberg, Wockel, Wischnewsky (bib14) 2018; 40 Parise, Caggiano (bib17) 2014; 2014 Houze de l’Aulnoit, Rogoz, Pinçon, Houzé de l’Aulnoit (bib3) 2018; 37 Mariotto, Etzioni, Hurlbert, Penberthy, Mayer (bib4) 2017; 26 Possinger, Wagner, Langecker, Wilmanns (bib20) 1987; 14 Goldhirsch, Wood, Coates (bib16) 2011; 22 Wolters, Regierer, Schwentner (bib15) 2012; 48 Largillier, Ferrero, Doyen (bib21) 2008; 19 Bartmann, Wischnewsky, Stüber (bib2) 2017; 295 Wockel, Varga, Atassi (bib13) 2010; 33 Turner, Slamon, Ro (bib8) 2018; 379 Lips, Mulder, de Ronde (bib19) 2013; 140 Lobbezoo, van Kampen, Voogd (bib27) 2015; 112 Prat, Karginova, Parker (bib25) 2013; 142 Regierer, Wolters, Ufen (bib11) 2014; 25 Sledge, Toi, Neven (bib7) 2017; 35 von Minckwitz, Untch, Blohmer (bib18) 2012; 30 Ufen, Köhne, Wischneswky (bib12) 2014; 25 (bib1) 2016 Iwata, Im, Masuda (bib6) 2017; 3 Krop, Kim, Martin (bib10) 2017; 18 Goldhirsch (10.1016/j.clbc.2019.04.015_bib16) 2011; 22 (10.1016/j.clbc.2019.04.015_bib1) 2016 Regierer (10.1016/j.clbc.2019.04.015_bib11) 2014; 25 Lips (10.1016/j.clbc.2019.04.015_bib19) 2013; 140 Puente (10.1016/j.clbc.2019.04.015_bib22) 2010; 122 Bartmann (10.1016/j.clbc.2019.04.015_bib2) 2017; 295 Wolters (10.1016/j.clbc.2019.04.015_bib15) 2012; 48 Slamon (10.1016/j.clbc.2019.04.015_bib5) 2018; 36 Ufen (10.1016/j.clbc.2019.04.015_bib12) 2014; 25 Possinger (10.1016/j.clbc.2019.04.015_bib20) 1987; 14 Parise (10.1016/j.clbc.2019.04.015_bib17) 2014; 2014 Wockel (10.1016/j.clbc.2019.04.015_bib13) 2010; 33 Lobbezoo (10.1016/j.clbc.2019.04.015_bib27) 2015; 112 Sledge (10.1016/j.clbc.2019.04.015_bib7) 2017; 35 Perou (10.1016/j.clbc.2019.04.015_bib24) 2000; 406 Lindstrom (10.1016/j.clbc.2019.04.015_bib26) 2012; 30 Prat (10.1016/j.clbc.2019.04.015_bib25) 2013; 142 Kreienberg (10.1016/j.clbc.2019.04.015_bib14) 2018; 40 Swain (10.1016/j.clbc.2019.04.015_bib9) 2015; 372 Mariotto (10.1016/j.clbc.2019.04.015_bib4) 2017; 26 von Minckwitz (10.1016/j.clbc.2019.04.015_bib18) 2012; 30 Iwata (10.1016/j.clbc.2019.04.015_bib6) 2017; 3 Largillier (10.1016/j.clbc.2019.04.015_bib21) 2008; 19 Krop (10.1016/j.clbc.2019.04.015_bib10) 2017; 18 Houze de l’Aulnoit (10.1016/j.clbc.2019.04.015_bib3) 2018; 37 Xiong (10.1016/j.clbc.2019.04.015_bib23) 2018; 50 Turner (10.1016/j.clbc.2019.04.015_bib8) 2018; 379 |
| References_xml | – volume: 36 start-page: 2465 year: 2018 end-page: 2472 ident: bib5 article-title: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 publication-title: J Clin Oncol contributor: fullname: Chia – volume: 3 start-page: 289 year: 2017 end-page: 303 ident: bib6 article-title: PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients publication-title: J Glob Oncol contributor: fullname: Masuda – volume: 30 start-page: 2601 year: 2012 end-page: 2608 ident: bib26 article-title: Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression publication-title: J Clin Oncol contributor: fullname: Wilking – volume: 112 start-page: 1445 year: 2015 end-page: 1451 ident: bib27 article-title: Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? publication-title: Br J Cancer contributor: fullname: Voogd – year: 2016 ident: bib1 article-title: A.o.t. Bericht zum Krebsgeschehen in Deutschland, 2016 – volume: 122 start-page: 591 year: 2010 end-page: 600 ident: bib22 article-title: Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register publication-title: Breast Cancer Res Treat contributor: fullname: Ruiz – volume: 30 start-page: 1796 year: 2012 end-page: 1804 ident: bib18 article-title: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes publication-title: J Clin Oncol contributor: fullname: Blohmer – volume: 26 start-page: 809 year: 2017 end-page: 815 ident: bib4 article-title: Estimation of the number of women living with metastatic breast cancer in the United States publication-title: Cancer Epidemiol Biomarkers Prev contributor: fullname: Mayer – volume: 25 start-page: 95 year: 2014 end-page: 100 ident: bib12 article-title: Metastatic breast cancer: are we treating the same patients as in the past? publication-title: Ann Oncol contributor: fullname: Wischneswky – volume: 140 start-page: 63 year: 2013 end-page: 71 ident: bib19 article-title: Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response publication-title: Breast Cancer Res Treat contributor: fullname: de Ronde – volume: 48 start-page: 1 year: 2012 end-page: 11 ident: bib15 article-title: A comparison of international breast cancer guidelines - do the national guidelines differ in treatment recommendations? publication-title: Eur J Cancer contributor: fullname: Schwentner – volume: 25 start-page: 633 year: 2014 end-page: 638 ident: bib11 article-title: An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients publication-title: Ann Oncol contributor: fullname: Ufen – volume: 35 start-page: 2875 year: 2017 end-page: 2884 ident: bib7 article-title: MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy publication-title: J Clin Oncol contributor: fullname: Neven – volume: 142 start-page: 237 year: 2013 end-page: 255 ident: bib25 article-title: Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes publication-title: Breast Cancer Res Treat contributor: fullname: Parker – volume: 37 start-page: 80 year: 2018 end-page: 88 ident: bib3 article-title: Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience publication-title: Breast contributor: fullname: Houzé de l’Aulnoit – volume: 379 start-page: 1926 year: 2018 end-page: 1936 ident: bib8 article-title: Overall survival with palbociclib and fulvestrant in advanced breast cancer publication-title: N Engl J Med contributor: fullname: Ro – volume: 14 start-page: 263 year: 1987 end-page: 274 ident: bib20 article-title: Treatment toxicity reduction: breast cancer publication-title: Cancer Treat Rev contributor: fullname: Wilmanns – volume: 50 start-page: 1260 year: 2018 end-page: 1269 ident: bib23 article-title: Score for the survival probability in metastasis breast cancer: a nomogram-based risk assessment model publication-title: Cancer Res Treat contributor: fullname: Huang – volume: 406 start-page: 747 year: 2000 end-page: 752 ident: bib24 article-title: Molecular portraits of human breast tumours publication-title: Nature contributor: fullname: Eisen – volume: 40 start-page: 54 year: 2018 end-page: 59 ident: bib14 article-title: Highly significant improvement in guideline adherence, relapse-free and overall survival in breast cancer patients when treated at certified breast cancer centres: an evaluation of 8323 patients publication-title: Breast contributor: fullname: Wischnewsky – volume: 18 start-page: 743 year: 2017 end-page: 754 ident: bib10 article-title: Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial publication-title: Lancet Oncol contributor: fullname: Martin – volume: 295 start-page: 211 year: 2017 end-page: 223 ident: bib2 article-title: Pattern of metastatic spread and subcategories of breast cancer publication-title: Arch Gynecol Obstet contributor: fullname: Stüber – volume: 2014 start-page: 469251 year: 2014 ident: bib17 article-title: Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers publication-title: J Cancer Epidemiol contributor: fullname: Caggiano – volume: 19 start-page: 2012 year: 2008 end-page: 2019 ident: bib21 article-title: Prognostic factors in 1,038 women with metastatic breast cancer publication-title: Ann Oncol contributor: fullname: Doyen – volume: 33 start-page: 21 year: 2010 end-page: 28 ident: bib13 article-title: Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study publication-title: Onkologie contributor: fullname: Atassi – volume: 372 start-page: 724 year: 2015 end-page: 734 ident: bib9 article-title: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer publication-title: N Engl J Med contributor: fullname: Kim – volume: 22 start-page: 1736 year: 2011 end-page: 1747 ident: bib16 article-title: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 publication-title: Ann Oncol contributor: fullname: Coates – volume: 25 start-page: 95 year: 2014 ident: 10.1016/j.clbc.2019.04.015_bib12 article-title: Metastatic breast cancer: are we treating the same patients as in the past? publication-title: Ann Oncol doi: 10.1093/annonc/mdt429 contributor: fullname: Ufen – volume: 379 start-page: 1926 year: 2018 ident: 10.1016/j.clbc.2019.04.015_bib8 article-title: Overall survival with palbociclib and fulvestrant in advanced breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1810527 contributor: fullname: Turner – volume: 3 start-page: 289 year: 2017 ident: 10.1016/j.clbc.2019.04.015_bib6 publication-title: J Glob Oncol contributor: fullname: Iwata – volume: 25 start-page: 633 year: 2014 ident: 10.1016/j.clbc.2019.04.015_bib11 article-title: An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients publication-title: Ann Oncol doi: 10.1093/annonc/mdt539 contributor: fullname: Regierer – volume: 122 start-page: 591 year: 2010 ident: 10.1016/j.clbc.2019.04.015_bib22 article-title: Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-009-0687-4 contributor: fullname: Puente – volume: 30 start-page: 1796 year: 2012 ident: 10.1016/j.clbc.2019.04.015_bib18 article-title: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes publication-title: J Clin Oncol doi: 10.1200/JCO.2011.38.8595 contributor: fullname: von Minckwitz – volume: 142 start-page: 237 year: 2013 ident: 10.1016/j.clbc.2019.04.015_bib25 article-title: Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-013-2743-3 contributor: fullname: Prat – volume: 112 start-page: 1445 year: 2015 ident: 10.1016/j.clbc.2019.04.015_bib27 article-title: Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? publication-title: Br J Cancer doi: 10.1038/bjc.2015.127 contributor: fullname: Lobbezoo – volume: 30 start-page: 2601 year: 2012 ident: 10.1016/j.clbc.2019.04.015_bib26 article-title: Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression publication-title: J Clin Oncol doi: 10.1200/JCO.2011.37.2482 contributor: fullname: Lindstrom – volume: 26 start-page: 809 year: 2017 ident: 10.1016/j.clbc.2019.04.015_bib4 article-title: Estimation of the number of women living with metastatic breast cancer in the United States publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-16-0889 contributor: fullname: Mariotto – volume: 295 start-page: 211 year: 2017 ident: 10.1016/j.clbc.2019.04.015_bib2 article-title: Pattern of metastatic spread and subcategories of breast cancer publication-title: Arch Gynecol Obstet doi: 10.1007/s00404-016-4225-4 contributor: fullname: Bartmann – volume: 36 start-page: 2465 year: 2018 ident: 10.1016/j.clbc.2019.04.015_bib5 article-title: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.78.9909 contributor: fullname: Slamon – volume: 40 start-page: 54 year: 2018 ident: 10.1016/j.clbc.2019.04.015_bib14 article-title: Highly significant improvement in guideline adherence, relapse-free and overall survival in breast cancer patients when treated at certified breast cancer centres: an evaluation of 8323 patients publication-title: Breast doi: 10.1016/j.breast.2018.04.002 contributor: fullname: Kreienberg – year: 2016 ident: 10.1016/j.clbc.2019.04.015_bib1 – volume: 50 start-page: 1260 year: 2018 ident: 10.1016/j.clbc.2019.04.015_bib23 article-title: Score for the survival probability in metastasis breast cancer: a nomogram-based risk assessment model publication-title: Cancer Res Treat doi: 10.4143/crt.2017.443 contributor: fullname: Xiong – volume: 140 start-page: 63 year: 2013 ident: 10.1016/j.clbc.2019.04.015_bib19 article-title: Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-013-2620-0 contributor: fullname: Lips – volume: 33 start-page: 21 year: 2010 ident: 10.1016/j.clbc.2019.04.015_bib13 article-title: Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study publication-title: Onkologie doi: 10.1159/000264617 contributor: fullname: Wockel – volume: 22 start-page: 1736 year: 2011 ident: 10.1016/j.clbc.2019.04.015_bib16 article-title: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 publication-title: Ann Oncol doi: 10.1093/annonc/mdr304 contributor: fullname: Goldhirsch – volume: 18 start-page: 743 year: 2017 ident: 10.1016/j.clbc.2019.04.015_bib10 article-title: Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30313-3 contributor: fullname: Krop – volume: 37 start-page: 80 year: 2018 ident: 10.1016/j.clbc.2019.04.015_bib3 article-title: Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience publication-title: Breast doi: 10.1016/j.breast.2017.10.008 contributor: fullname: Houze de l’Aulnoit – volume: 35 start-page: 2875 year: 2017 ident: 10.1016/j.clbc.2019.04.015_bib7 article-title: MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2017.73.7585 contributor: fullname: Sledge – volume: 48 start-page: 1 year: 2012 ident: 10.1016/j.clbc.2019.04.015_bib15 article-title: A comparison of international breast cancer guidelines - do the national guidelines differ in treatment recommendations? publication-title: Eur J Cancer doi: 10.1016/j.ejca.2011.06.020 contributor: fullname: Wolters – volume: 19 start-page: 2012 year: 2008 ident: 10.1016/j.clbc.2019.04.015_bib21 article-title: Prognostic factors in 1,038 women with metastatic breast cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdn424 contributor: fullname: Largillier – volume: 14 start-page: 263 year: 1987 ident: 10.1016/j.clbc.2019.04.015_bib20 article-title: Treatment toxicity reduction: breast cancer publication-title: Cancer Treat Rev doi: 10.1016/0305-7372(87)90017-X contributor: fullname: Possinger – volume: 2014 start-page: 469251 year: 2014 ident: 10.1016/j.clbc.2019.04.015_bib17 article-title: Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers publication-title: J Cancer Epidemiol contributor: fullname: Parise – volume: 372 start-page: 724 year: 2015 ident: 10.1016/j.clbc.2019.04.015_bib9 article-title: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1413513 contributor: fullname: Swain – volume: 406 start-page: 747 year: 2000 ident: 10.1016/j.clbc.2019.04.015_bib24 article-title: Molecular portraits of human breast tumours publication-title: Nature doi: 10.1038/35021093 contributor: fullname: Perou |
| SSID | ssj0026310 |
| Score | 2.2628424 |
| Snippet | The B2 Prognostic Score (B2PS) is a clinical decision-making tool in metastatic breast cancer (MBC) that provides risk classification based on routine... BACKGROUNDThe B2 Prognostic Score (B2PS) is a clinical decision-making tool in metastatic breast cancer (MBC) that provides risk classification based on... |
| SourceID | proquest crossref elsevier |
| SourceType | Aggregation Database Publisher |
| StartPage | 333 |
| SubjectTerms | Intrinsic subgroups Metastatic breast cancer Prognostic score Survival |
| Title | B2 Prognostic Score: External Validation of a Clinical Decision-making Tool for Metastatic Breast Cancer |
| URI | https://dx.doi.org/10.1016/j.clbc.2019.04.015 https://search.proquest.com/docview/2253833784 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELa6uxLigniKZQEZiVsU1NTOw9y2D7SsVC4t0FvkV8RWbIq27f_fmdhOskUgQOIStVbipJ6v42-cmc-EvDVZqkQieSy4KWLO2SiWqWGxYJoDphR3VWkXi_zTqpjO-GwwCLvjdW3_1dLQBrbGytm_sHbbKTTAZ7A5HMHqcPwju49xW6YNps-hFOsCVSox6p95tefoCxBv0_JEGU1CaeTU77YTXzcbVEVLVOfEJMS53UmsO4LuxpjCvosmCJWbPq9te1HuDN2d0SQN78GKDhuyXkvw6ab3Pv_rFYTYSO_dOu5c1lXYQLRJFcL6xJ3LQbN1O41MIcbf-nKdSywLu7ruL2Ekok2G8-tqobbmTuonEIssBn7iHKp1bQLcM0Zcd_y36OE07Tlj5iQ2_LzOnGjST1OGW71Yv9PfFUpaJqKRvnU1pgdS3At8Jnwk8IMQCuarI3IyAgcH_vXk_ONsddmG-hlzOhjhN_hyLZdZeHinX1GiA3LQMJ7lQ_LAhyr03GHsERnY-jG5N_fJGE_It_GIdlCjDdTe0wA02gGNbioqaYAIPQAaRaBRABrtgEYd0KgD2lPy-cNsObmI_cYdsQb6yOPEYnmzTpQFvq70sGJyaKTQUlYyL7SuWFVUlVCp1ZlFNSMIMpjJEwtfZAYz3jNyXG9q-5xQsLWptNGjPBOcSVbIjClVFHCJYmwoTkkUxq784fRZypC4uC5xpEsc6XLISxjpU5KG4S09w3TMsQQ0_Pa6N8EWJbhffKcma7vZb0uYDlnBWF7wF__Y9xm53_0nXpLj3c3eviJHW7N_7VF1C_GGqdE |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=B2+Prognostic+Score%3A+External+Validation+of+a+Clinical+Decision-making+Tool+for+Metastatic+Breast+Cancer&rft.jtitle=Clinical+breast+cancer&rft.au=Stueber%2C+Tanja+Nadine&rft.au=Wischnewsky%2C+Manfred&rft.au=Leinert%2C+Elena&rft.au=Diessner%2C+Joachim&rft.date=2019-10-01&rft.pub=Elsevier+Inc&rft.issn=1526-8209&rft.eissn=1938-0666&rft.volume=19&rft.issue=5&rft.spage=333&rft.epage=339&rft_id=info:doi/10.1016%2Fj.clbc.2019.04.015&rft.externalDocID=S152682091830867X |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1526-8209&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1526-8209&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1526-8209&client=summon |